<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102545">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946360</url>
  </required_header>
  <id_info>
    <org_study_id>ACLF-MBT</org_study_id>
    <nct_id>NCT01946360</nct_id>
  </id_info>
  <brief_title>Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood will be collected after venepuncture from all patients for complete blood counts,
      Serum bilirubin (direct and indirect), aspartate aminotransferase, alanine aminotransferase,
      alkaline phosphatase, gamma glutamyl transferase, prothrombin time and INR, urea,
      creatinine, sodium, potassium, serum total protein and albumin, within 24 hours after
      admission and twice a week there after or as and when needed.

      Time line for blood tests and evaluation of clinical parameters &amp; 13C-MBT

      For ALF patients:

      On days 0, 1, 3, and 7

      For ACLF patients:

      On days 0, 7 (week 1), 14(week 2), 28 (weeks 4)

      Blood tests would include:

      Serum bilirubin (total and direct), aspartate aminotransferase, alanine aminotransferase,
      alkaline phosphatase, gamma-glutamyltransferase, Serum proteins (total and albumin),
      prothrombin time &amp; international normalized ratio (INR),  Serum urea and creatinine, serum
      electrolytes, arterial ammonia and arterial blood gas analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Survival or Transplantation for Acute Liver Failure (ALF).</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality or Transplantation for Acute on Chronic Liver Failure (ACLF) patients.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Acute Liver Failure</condition>
  <condition>Acute on Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>ACLF and Acute Liver Failure (ALF)..</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and  on day 0,1,3,7 in Acute Liver failure (ALF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Methacetin Breath Test in ACLF and ALF patients</intervention_name>
    <description>Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).</description>
    <arm_group_label>ACLF and Acute Liver Failure (ALF)..</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients presenting with acute liver failure and acute on chronic liver failure
        (between 18 - 70 years of age) to Institute of Liver &amp; Biliary Sciences (ILBS), New Delhi,
        India.

        Exclusion Criteria:

          1. Patients with significant co-morbid illnesses such as cardiovascular or respiratory
             or intrinsic renal diseases which by themselves may have a bearing on the outcome.

          2. Patients with previous intestinal bypass surgery for morbid obesity

          3. Patients with extensive small bowel resection

          4. Patients currently receiving total parenteral nutrition

          5. Pregnant women

          6. Patients with history of allergy to paracetamol

          7. Patients on steroids or anti-fungal agents

          8. Patients in encephalopathy

          9. Patients unwilling to participate in the protocol

         10. Patients on medications which can alter the activity of CYP 1A2 enzymes such as
             corticosteroids, amiodarone, tetracycline, niacin, valproic acid, methotrexate,
             stavudine and zidovudine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Shiv Kumar Sarin, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Chitranshu Vashishtha, DM</last_name>
    <phone>011-46300000</phone>
    <phone_ext>1042</phone_ext>
    <email>chitranshuv@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Ankit Bhardwaj</last_name>
    <phone>011-46300000</phone>
    <phone_ext>1032</phone_ext>
    <email>bhardwaj.ankit3@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
